# V1 Empirics Check — openai/gpt-5.4 (Variant A)

**Model:** openai/gpt-5.4
**Variant:** A
**Date:** 2026-03-30T11:10:11.202196

---

## 1. Idea Fidelity

The paper broadly follows the manifest’s core idea: it uses ARCOS transaction data to construct county-level distributor concentration, studies whether wholesaler market structure affected opioid pill supply, and uses a shift-share/Bartik-style IV based on national merger waves. It also adds the intended secondary health outcome (overdose mortality).

That said, the implementation departs from the original identification strategy in important ways. The manifest envisioned an instrument tied to specific merger-induced changes in distributor structure. The paper instead instruments county HHI with a predicted HHI built from each distributor’s **national opioid market share over time**. This is a much broader object than merger exposure: national share changes may reflect opioid-demand shocks, product mix shifts, enforcement actions, entry/exit, or changing pharmacy relationships, not just mergers. As written, the IV is therefore less “merger-driven” than the paper claims. In addition, the baseline year is 2006, even though one featured merger (McKesson-D&K) occurred in 2006, so the pre-period is not clearly pre-merger.

So the paper pursues the original question, but the identification strategy is a looser version of the manifest’s design and currently misses the key step of cleanly isolating merger-driven variation from broader national changes in opioid distribution.

## 2. Summary

This paper asks whether pharmaceutical distributor concentration affected the geography of opioid pill supply during 2006–2012. Using ARCOS transaction data, the authors construct county-year HHIs of distributor concentration and estimate that higher concentration reduced pills per capita, implying that competition among wholesalers may have amplified opioid shipments.

The question is interesting and potentially important. However, the causal interpretation currently rests on an IV strategy whose exclusion restriction and exogeneity are not yet convincing enough for the paper’s headline conclusion.

## 3. Essential Points

1. **The instrument is not convincingly merger-driven and likely violates the exclusion restriction.**  
   The paper’s instrument uses national distributor opioid shares \(S_{dt}\), but these shares are themselves outcomes of national opioid-market developments. If national shifts in McKesson/Cardinal/ABC shares reflect DEA scrutiny, evolving suspicious-order monitoring, manufacturer relationships, the reformulation of OxyContin, hydrocodone/oxycodone demand trends, or broader changes in pharmacy networks, then the instrument captures much more than mergers. Those same forces could affect county pill supply directly, violating exclusion. The paper needs to isolate merger-specific shocks much more cleanly.

2. **The shift-share design relies on endogenous baseline shares and very few shocks.**  
   County exposure is determined by 2006 distributor composition, but those baseline shares may already reflect local opioid demand, prescribing culture, pharmacy type, chain penetration, and rural logistics. With only a handful of merger events, the identifying variation is thin, and standard Bartik concerns are especially acute. The paper needs to engage the modern shift-share literature more seriously and show identification comes from plausibly exogenous shocks rather than pre-existing county sorting.

3. **The empirical specification does not yet match the mechanism the paper wants to test.**  
   The paper interprets HHI causally as “competition vs. concentration,” but HHI is constructed from **opioid shipments themselves**. That makes the treatment partly an outcome of the opioid market rather than an independent measure of wholesale market structure. Moreover, the proposed mechanism is about distributors’ overall market power and compliance incentives, but the measured HHI is opioid-specific and county-specific. The authors need to show that this is the right treatment variable for the mechanism, or else redefine treatment using broader wholesaler exposure not mechanically tied to opioid volume.

## 4. Suggestions

This is a promising paper with a genuinely novel question, and I would encourage the authors to keep working on it. But to be publishable in a top field journal—and certainly in AER: Insights format—the design needs to become much sharper. Below are suggestions that, if implemented well, could substantially improve the paper.

**1. Rebuild the IV around discrete merger exposure rather than aggregate national share drift.**  
The cleanest revision would be to move away from \(S_{dt}/S_{d,2006}\) as the core “shift” and instead construct exposure to specific mergers:
- county baseline share of D&K interacted with post-2006 years;
- county baseline share of Kinray interacted with post-2010 years;
- possibly county baseline share of identified Amerisource regional entities interacted with the relevant consolidation years.

That would make the design much closer to an event-study or stacked difference-in-differences with heterogeneous exposure, and much easier to interpret. Right now, the paper says “merger waves” but estimates something closer to “counties more exposed to national changes in distributor opioid shares.” Those are not the same.

**2. Show merger timing and geography visually and transparently.**  
A strong figure would plot, for each acquired distributor, its 2006 county footprint and how concentration changed after the merger. Another useful figure would show event-time coefficients for high- versus low-exposure counties around each merger. If the identification is real, counties with more D&K exposure should see a break after 2006, and counties with more Kinray exposure should see a break after 2010, with limited pre-trends.

**3. Conduct explicit pre-trend and placebo tests.**  
This is essential. In the current FE-IV framework, a balance table on demographic covariates is not enough. I would want:
- pre-trend tests using earlier ARCOS years if available, or at least placebo outcomes within the sample;
- placebo mergers assigned to false years;
- placebo exposure based on distributors not involved in mergers;
- placebo outcomes unlikely to respond to opioid wholesaler consolidation.

If the authors can access ARCOS for non-opioid controlled substances, that would be especially useful. If merger exposure predicts shipments of unrelated drugs similarly, the interpretation would shift away from opioid-specific competition and toward generic wholesaler changes.

**4. Clarify whether the treatment is market structure or operational disruption.**  
A major concern is that mergers may temporarily disrupt logistics, warehouse integration, account reassignment, or compliance screening. If so, the reduced supply after concentration may have little to do with “market power” and more to do with transition frictions. The paper acknowledges this as a threat but does not really test it. A useful approach would be to distinguish short-run merger windows from persistent post-merger periods. If effects are transient, the current interpretation is too strong.

**5. Address DEA enforcement as a confounding national shock.**  
The paper itself notes enforcement actions against McKesson and Cardinal. That is precisely the kind of national shock that could move both national shares and local shipments. If counties with high baseline exposure to those distributors subsequently receive fewer pills because those firms are under scrutiny, the estimate may reflect differential compliance shocks, not competition. I would encourage the authors to:
- control for exposure to distributors facing enforcement actions;
- exclude windows immediately surrounding major enforcement episodes;
- or explicitly reinterpret the design as capturing concentration plus compliance intensity, if that is what the data support.

**6. Reconsider the treatment variable.**  
HHI based on opioid dosage units is intuitive, but it is mechanically close to the outcome of interest. The paper would be stronger if it could measure county-year wholesaler structure using a broader denominator, ideally all pharmaceutical shipments handled by these distributors, not just opioids. If that is impossible in ARCOS, then at minimum the paper should:
- be explicit that the treatment is **opioid-distributor concentration**, not wholesaler market structure generally;
- show results with alternative measures: top-1 share, top-3 share, effective number of distributors, entrant count, or distributor share entropy;
- show that the sign is not an artifact of HHI’s construction.

**7. Tighten the interpretation of the estimated effect.**  
The current headline—“competition amplified the flood”—is stronger than the evidence. The point estimate is only marginally significant, mortality evidence is reduced-form and also marginal, and one robustness check (log outcome) flips sign. I would strongly recommend softening the language unless the redesigned identification becomes more compelling. Something like “counties exposed to merger-induced concentration experienced lower pill shipments” would be more defensible.

**8. Strengthen inference.**  
State-clustered standard errors with 49 clusters are not obviously inappropriate, but given the design and the leave-one-state-out emphasis, I would also report:
- wild-cluster bootstrap \(p\)-values;
- randomization-inference or permutation-based inference if feasible;
- AKM/Adão-Kolesár-Morales style shift-share inference if the authors keep a Bartik framework.

The leave-one-out exercise is useful descriptively, but it is not a substitute for valid inference tailored to shift-share designs.

**9. Better motivate sample construction and missingness.**  
The appendix reports a 94.6% county match rate, meaning nontrivial data are dropped. The paper should show whether unmatched counties are systematically different. Likewise, the county count changes from the 3,100 in the manifest to 2,937 in the paper; this needs a clear accounting. For a short paper, one appendix table on sample attrition would suffice.

**10. Be more careful with the overdose outcome.**  
The mortality analysis is interesting but currently too underdeveloped for a causal interpretation. Overdose deaths are affected by many factors and may not respond contemporaneously to county pill shipments. If retained, this should be framed as suggestive. A more compelling secondary outcome would be an intermediate measure—e.g., high-dosage shipment intensity, oxycodone share, or shipments to independent pharmacies versus chains—if those are observable.

**11. Connect more directly to the antitrust and opioid literatures.**  
The paper’s contribution would be sharper if it distinguished between two hypotheses:
- concentration reduces harmful output through internalization/compliance;
- concentration reduces output through ordinary market power and higher prices/service changes.

Those are quite different policy interpretations. The current discussion jumps quickly to “competition is bad here,” but antitrust implications depend critically on mechanism. If possible, show heterogeneity where compliance concerns should matter more: counties with more independent pharmacies, weaker state PDMPs, historically high suspicious-order exposure, or regions more reliant on acquired distributors.

**12. Consider a simpler research design if the merger-IV remains weak conceptually.**  
The question is good enough that the paper could still work with a more transparent reduced-form design:
- exploit exposure to specific acquisitions in a diff-in-diff/event-study;
- use warehouse closures or DEA suspension orders as quasi-experiments;
- study whether counties more reliant on sanctioned distributors saw relative shipment declines.

That may ultimately be more credible than an all-purpose Bartik instrument built from national share changes.

Overall, I think the paper has a novel and policy-relevant idea, and the ARCOS data are well suited to studying wholesaler behavior. But the current version overstates how cleanly national mergers identify the causal effect of concentration. If the authors can re-anchor the design in clearly dated, merger-specific shocks and provide event-study evidence with stronger falsification tests, the paper could become a valuable contribution. As written, the empirical strategy is not yet credible enough to support the paper’s central claim.
